Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Dojolvi Generic Name & Formulations
Legal Class
Rx
General Description
Triheptanoin 100% w/w; oral liq; provides 8.3kcal/mL.
Pharmacological Class
Medium-chain triglyceride.
How Supplied
Liq—500mL
Manufacturer
Generic Availability
NO
Mechanism of Action
Triheptanoin provides a source of calories and fatty acids to bypass the long-chain FAOD enzyme deficiencies for energy production and replacement.
Dojolvi Indications
Indications
As a source of calories and fatty acids for the treatment of patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Dojolvi Dosage and Administration
Adults and Children
See full labeling. Discontinue other MCT products prior to initiation. Determine daily caloric intake (DCI) prior to calculating dose. Total daily dose (mL) = Patients DCI (kcal) x Target % doses of DCI/8.3 (kcal/mL) of Dojolvi. Give at mealtimes or with snacks. Administer dose mixed with semi-solid food or liquids (eg, yogurt, milk, formula, cottage cheese, hot cereal, applesauce, baby food, others) orally or enterally via feeding tube. Target daily dose: up to 35% of total prescribed DCI in at least 4 divided doses. Not currently taking medium-chain triglyceride (MCT) product: initiate at total daily dose of ~10% DCI in at least 4 divided doses, then increase up to 35% DCI over 2–3 weeks. Switching from another MCT product: initiate at last tolerated MCT daily dose in at least 4 divided doses, then increase by ~5% DCI every 2–3 days until up to 35% DCI is achieved.
Dojolvi Contraindications
Not Applicable
Dojolvi Boxed Warnings
Not Applicable
Dojolvi Warnings/Precautions
Warnings/Precautions
Incompatible with certain plastics. Do not use polystyrene or polyvinyl chloride (PVC) plastics for preparation or administration. Monitor containers, dosing components/utensils, or feeding tubes regularly to ensure proper functioning and integrity. Monitor total caloric intake during dose titration (esp. in those with GI adverse reactions) and adjust as needed. If GI reactions occur, consider dose reduction until symptoms resolved. Avoid in pancreatic insufficiency. Neonates: may require higher fat intake. Pregnancy. Nursing mothers.
Dojolvi Pharmacokinetics
Distribution
Plasma protein bound: ~80%.
Elimination
Renal.
Dojolvi Interactions
Interactions
Avoid use with pancreatic lipase inhibitors (eg, orlistat).
Dojolvi Adverse Reactions
Adverse Reactions
Abdominal pain, diarrhea, vomiting, nausea.
Dojolvi Clinical Trials
See Literature
Dojolvi Note
Not Applicable
Dojolvi Patient Counseling
See Literature
